분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-03-08 15:43:18 , Hit : 1728
 Merck hepatitis C drugs work in HIV co-infected patients -study

March 5  Wed Mar 5, 2014 5:56pm EST

0 Comments

(Reuters) - A combination of oral drugs for hepatitis C developed by Merck & Co appeared to be well tolerated and highly effective in treating the liver disease in patients also infected with HIV, according to data from a midstage clinical trial presented on Wednesday.

The Merck drugs, MK-5172 and MK-8742, which belong to promising new classes of anti-viral medicines, were tested over a 12-week course of treatment both with and without the older hepatitis C drug ribavirin in co-infected patients.

After 12 weeks of treatment, all 29 patients who received the two Merck drugs and ribavirin had undetectable levels of the hepatitis C virus. Among those who got just the experimental Merck drugs, 26 of 29, or 90 percent, appeared to have the hepatitis C virus eliminated from their blood.

If the virus remains undetectable 12 weeks after completion of treatment, those patients are considered cured.

The available data from the ongoing study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. More detailed results of the study dubbed C-Worthy are expected to be presented at a European medical meeting in April, Merck said.

No co-infected patients discontinued treatment due to either an adverse side effect or study medication intolerance, Merck said. The most common side effects of fatigue and headache were no more prevalent in patients with hepatitis C and HIV infection than what had been observed in patients with hepatitis C alone.

A new era in treatment for the serious liver disease has begun with several companies, including Gilead Sciences Inc , AbbVie and Bristol-Myers Squibb Co, developing all oral treatment regimens that have demonstrated cure rates well in excess of 90 percent with treatment durations of just 12 weeks or shorter.

Current standard treatments take 24 to 48 weeks and include the injected drug interferon that causes miserable flu-like symptoms and cure about 75 percent of patients.

Those also living with the virus that causes AIDS are an important patient population.

About seven million people worldwide are co-infected with HIV and hepatitis C (HCV). Co-infected patients have a three times higher rate of progression to cirrhosis and a six times higher risk of liver decompression than those with HCV alone.







847   CRISPR Reverses Disease Symptoms in Living Animals for First Time  이성욱 2014/04/01 1685
846   약물 생산을 보다 저렴하고 환경친화적으로 만드는데 도움을 주는 바이오 역합성  이성욱 2014/03/26 2112
845   J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator  이성욱 2014/03/24 2017
844   스트레스를 받는 뇌세포는 알츠하이머로부터 보호작용을 한다  이성욱 2014/03/24 1928
843   RNA 치료제 등 3대 R&D 트렌드  이성욱 2014/03/18 2016
842   막다른 골목에 몰린 STAP 세포  이성욱 2014/03/18 1929
841   암 세포의 혈관 밖 이동을 돕는 자외선  이성욱 2014/03/13 2166
840   유전자 편집방법을 이용한 HIV 치료  이성욱 2014/03/10 2081
  Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1728
838   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1659
837   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1816
836   인체 '게놈 분석 1000달러 시대' 왔다  이성욱 2014/02/28 2110
835   FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation  이성욱 2014/02/26 2038
834   숙주 세포 핵의 바아러스 DNA 분해  이성욱 2014/02/26 2275
833   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2105
832   자궁경부암 유발 바이러스에도 효과를 보이는 HIV 약물  이성욱 2014/02/21 2403
831   美 연구팀, ‘원숭이 아바타’ 실험 성공시켰다  이성욱 2014/02/20 2125
830   Small non-coding RNAs could be warning signs of cancer  이성욱 2014/02/18 1809
829   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2386
828   Researchers turn adult cells back into stem cells  이성욱 2014/01/30 1663

[이전 10개] [1]..[21] 22 [23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN